BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8231247)

  • 1. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA.
    Lange W; Cantin EM; Finke J; Dölken G
    Leukemia; 1993 Nov; 7(11):1786-94. PubMed ID: 8231247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
    James H; Mills K; Gibson I
    Leukemia; 1996 Jun; 10(6):1054-64. PubMed ID: 8667643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells.
    Lange W
    Klin Padiatr; 1995; 207(4):222-4. PubMed ID: 7564157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
    Wright LA; Milliken S; Biggs JC; Kearney P
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):15-23. PubMed ID: 9512092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L; Wilson SB; Milliken S; Biggs J; Kearney P
    Exp Hematol; 1993 Dec; 21(13):1714-8. PubMed ID: 8243570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH; Wu SC; Chen WS; Yen CC; Yang MH; Tsai YC; Chen PM
    Biochem Biophys Res Commun; 2004 Jun; 318(3):764-72. PubMed ID: 15144904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of multi-unit ribozymes on the growth inhibition and apoptosis induction of CML K562 cells].
    Feng Q; Sun B; Sun K; Shang Z; Wang S; Wang W; Zhao Y; Yan Z; Han W; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):435-9. PubMed ID: 12485492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M; Kuwabara T; Taira K
    Nucleic Acids Symp Ser; 1997; (37):213-4. PubMed ID: 9586075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction of retrovirus vector of bcr/abl mRNA cleaving ribozyme gene and its effects on K562 cells].
    Wu Y; Chen Y; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 1998 Dec; 19(12):623-6. PubMed ID: 11263328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LightCycler technology for the quantitation of bcr/abl fusion transcripts.
    Kreuzer KA; Lass U; Bohn A; Landt O; Schmidt CA
    Cancer Res; 1999 Jul; 59(13):3171-4. PubMed ID: 10397261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
    Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
    Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK; Nabissa PM; Reddy EP
    Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D; Hanenberg H; Lion T; Burdach S
    Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome.
    Warashina M; Kuwabara T; Nakamatsu Y; Taira K
    Chem Biol; 1999 Apr; 6(4):237-50. PubMed ID: 10099134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular biology of chronic myeloid leukaemia.
    Melo JV
    Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.